These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 25735844)

  • 21. Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model.
    Firsov AA; Smirnova MV; Lubenko IY; Vostrov SN; Portnoy YA; Zinner SH
    J Antimicrob Chemother; 2006 Dec; 58(6):1185-92. PubMed ID: 17028094
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model.
    LaPlante KL; Rybak MJ
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4665-72. PubMed ID: 15561842
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium.
    Jevitt LA; Smith AJ; Williams PP; Raney PM; McGowan JE; Tenover FC
    Microb Drug Resist; 2003; 9(4):389-93. PubMed ID: 15000746
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Susceptibility patterns of coagulase-negative staphylococci to several newer antimicrobial agents in comparison with vancomycin and oxacillin.
    Stuart JI; John MA; Milburn S; Diagre D; Wilson B; Hussain Z
    Int J Antimicrob Agents; 2011 Mar; 37(3):248-52. PubMed ID: 21295951
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Severe sepsis caused by a linezolid-resistant Enterococcus faecium in a 10-year-old girl after multiple trauma.
    Mutschler M; Trojan S; Defosse JM; Helmers A; Probst C; Bouillon B; Wappler F; Sakka SG
    Int J Infect Dis; 2013 Jun; 17(6):e466-7. PubMed ID: 23415582
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro activity of daptomycin against clinical isolates with reduced susceptibilities to linezolid and quinupristin/dalfopristin.
    Anastasiou DM; Thorne GM; Luperchio SA; Alder JD
    Int J Antimicrob Agents; 2006 Nov; 28(5):385-8. PubMed ID: 17046205
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates.
    Deville JG; Adler S; Azimi PH; Jantausch BA; Morfin MR; Beltran S; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB
    Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S158-63. PubMed ID: 14520141
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative bactericidal activities of daptomycin, glycopeptides, linezolid and tigecycline against blood isolates of Gram-positive bacteria in Taiwan.
    Huang YT; Liao CH; Teng LJ; Hsueh PR
    Clin Microbiol Infect; 2008 Feb; 14(2):124-9. PubMed ID: 18076671
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activity of ceftobiprole against methicillin-resistant Staphylococcus aureus strains with reduced susceptibility to daptomycin, linezolid or vancomycin, and strains with defined SCCmec types.
    Farrell DJ; Flamm RK; Sader HS; Jones RN
    Int J Antimicrob Agents; 2014 Apr; 43(4):323-7. PubMed ID: 24411474
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of soyasaponin I on TLR2 and TLR4 induced inflammation in the MUTZ-3-cell model.
    Fußbroich D; Schubert R; Schneider P; Zielen S; Beermann C
    Food Funct; 2015 Mar; 6(3):1001-10. PubMed ID: 25685945
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of Enterococcus faecalis on the bactericidal activities of arbekacin, daptomycin, linezolid, and tigecycline against methicillin-resistant Staphylococcus aureus in a mixed-pathogen pharmacodynamic model.
    LaPlante KL; Rybak MJ; Leuthner KD; Chin JN
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1298-303. PubMed ID: 16569844
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Analysis of treatments used in infections caused by gram-positive multiresistant cocci in critically ill patients admitted to the ICU].
    Álvarez-Lerma F; Palomar Martínez M; Olaechea Astigarraga P; Insausti Ordeñana J; López Pueyo MJ; Gracia Arnillas MP; Gimeno Costa R; Seijas Betolaza I
    Rev Esp Quimioter; 2012 Mar; 25(1):65-73. PubMed ID: 22488544
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rapid bactericidal activity of daptomycin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus peritonitis in mice as measured with bioluminescent bacteria.
    Mortin LI; Li T; Van Praagh AD; Zhang S; Zhang XX; Alder JD
    Antimicrob Agents Chemother; 2007 May; 51(5):1787-94. PubMed ID: 17307984
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Linezolid for the treatment of children with bacteremia or nosocomial pneumonia caused by resistant gram-positive bacterial pathogens.
    Jantausch BA; Deville J; Adler S; Morfin MR; Lopez P; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB
    Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S164-71. PubMed ID: 14520142
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro activity of telavancin compared with vancomycin and linezolid against Gram-positive organisms isolated from cancer patients.
    Rolston K; Wang W; Nesher L; Coyle E; Shelburne S; Prince RA
    J Antibiot (Tokyo); 2014 Jul; 67(7):505-9. PubMed ID: 24824818
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Concentration-response relationships as a basis for choice of the optimal endpoints of the antimicrobial effect: daptomycin and vancomycin pharmacodynamics with staphylococci in an in vitro dynamic model.
    Smirnova MV; Lubenko IY; Portnoy YA; Zinner SH; Firsov AA
    Int J Antimicrob Agents; 2007 Feb; 29(2):165-9. PubMed ID: 17207607
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New drugs for Gram-positive uropathogens.
    Wagenlehner FM; Naber KG
    Int J Antimicrob Agents; 2004 Sep; 24 Suppl 1():S39-43. PubMed ID: 15364305
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Linezolid for the treatment of resistant gram-positive cocci.
    Bain KT; Wittbrodt ET
    Ann Pharmacother; 2001 May; 35(5):566-75. PubMed ID: 11346064
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activity of vancomycin, ciprofloxacin, daptomycin, and linezolid against coagulase-negative staphylococci bacteremia.
    Fajardo Olivares M; Hidalgo Orozco R; Rodríguez Garrido S; Rodríguez-Vidigal FF; Vera Tomé A; Robles Marcos M
    Rev Esp Quimioter; 2011 Jun; 24(2):74-8. PubMed ID: 21666998
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro activity of linezolid and other antibiotics against Gram-positive bacteria from the major teaching hospitals in Kuwait.
    Al Sweih N; Mokaddas E; Jamal W; Phillips OA; Rotimi VO
    J Chemother; 2005 Dec; 17(6):607-13. PubMed ID: 16433190
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.